Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ISRG

Intuitive Surgical Inc

Apr 21 • 09:49AM ET

463.65

-1.95 -0.42 %

Healthcare • Medical Instruments & Supplies • USA • NASD

Today, 4:30 AMIntuitive Surgical Inc is scheduled to announce earnings today after market close. Analysts expect non-GAAP EPS of $2.12 and revenue of $2.6B

Peers: MDT SYK ABT JNJ BSX EW ZBH GMED TMDX

| Held by: VTI VOO QQQ IVV SPY VUG XLV IWF QQQM IHI

Index	NDX, S&P 500	P/E	58.87	EPS (ttm)	7.88	Insider Own	0.64%	Shs Outstand	355.10M	Perf Week	-0.76%
Market Cap	164.67B	Forward P/E	40.64	EPS next Y	11.41	Insider Trans	-6.41%	Shs Float	352.90M	Perf Month	-3.00%
Enterprise Value	159.03B	PEG	3.00	EPS next Q	2.12	Inst Own	85.67%	Short Float	1.91%	Perf Quarter	-12.09%
Income	2.86B	P/S	16.36	EPS this Y	11.90%	Inst Trans	0.33%	Short Ratio	3.51	Perf Half Y	3.93%
Sales	10.06B	P/B	9.24	EPS next Y	14.17%	ROA	14.47%	Short Interest	6.75M	Perf YTD	-18.14%
Book/sh	50.19	P/C	27.75	EPS next 5Y	13.56%	ROE	16.67%	52W High	603.88 -23.22%	Perf Year	-1.00%
Cash/sh	16.71	P/FCF	66.12	EPS past 3/5Y	29.18% 21.79%	ROIC	15.91%	52W Low	427.84 8.37%	Perf 3Y	54.44%
Dividend Est.	-	EV/EBITDA	44.50	Sales past 3/5Y	17.39% 18.22%	Gross Margin	65.98%	Volatility	2.52% 2.36%	Perf 5Y	56.04%
Dividend TTM	-	EV/Sales	15.80	EPS Y/Y TTM	22.44%	Oper. Margin	29.27%	ATR (14)	12.10	Perf 10Y	550.07%
Dividend Ex-Date	-	Quick Ratio	3.96	Sales Y/Y TTM	20.51%	Profit Margin	28.38%	RSI (14)	47.02	Recom	1.92
Dividend Gr. 3/5Y	- -	Current Ratio	4.87	EPS Q/Q	17.04%	SMA20	0.60%	Beta	1.56	Target Price	597.35
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	18.76%	SMA50	-3.21%	Rel Volume	1.13	Prev Close	465.60
Employees	17021	LT Debt/Eq	0.01	Earnings	Apr 21 AMC	SMA200	-7.70%	Avg Volume	1.92M	Price	463.65
IPO	Jun 13, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.58% 3.75%	Trades		Volume	209,490	Change	-0.42%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-26	Upgrade	Citigroup	Neutral → Buy	$590
Jan-27-26	Initiated	TD Cowen	Buy	$660
Dec-11-25	Downgrade	Citigroup	Buy → Neutral	$635
Jul-23-25	Downgrade	Erste Group	Buy → Hold
Jun-09-25	Downgrade	Deutsche Bank	Hold → Sell	$440
Jun-05-25	Upgrade	Erste Group	Hold → Buy
Dec-02-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$522 → $650
Aug-02-24	Upgrade	Redburn Atlantic	Neutral → Buy	$380 → $510
Jul-10-24	Reiterated	Citigroup	Buy	$462 → $512
May-30-24	Initiated	Goldman	Buy	$500
Nov-17-23	Initiated	HSBC Securities	Buy	$318
Jul-19-23	Initiated	Robert W. Baird	Outperform	$377
Apr-19-23	Reiterated	Wells Fargo	Overweight	$289 → $310
Apr-19-23	Reiterated	Truist	Buy	$300 → $325
Apr-19-23	Reiterated	Stifel	Buy	$285 → $315
Apr-19-23	Reiterated	RBC Capital Mkts	Outperform	$305 → $309
Apr-19-23	Reiterated	Raymond James	Outperform	$270 → $323
Apr-19-23	Reiterated	Morgan Stanley	Equal-Weight	$265 → $285
Apr-19-23	Reiterated	JP Morgan	Overweight	$250 → $335
Apr-19-23	Reiterated	Evercore ISI	In-line	$240 → $270

Show Previous Ratings

Apr-09-26 08:11PM	Can 13-15% Procedure Growth in 2026 Sustain ISRG's Premium Valuation? (Quartz)
Apr-08-26 09:31AM	Tired of AI and Oil? Buy the Robot. (Trefis)
Apr-03-26 07:38AM	Restore Robotics cleared to remanufacture 2 more da Vinci Xi instruments (MedTech Dive)
Mar-31-26 06:30AM	Can Boston Scientific Stock Surge 40% From Here? (Trefis)
Mar-24-26 11:03AM	Sonder Capital Closes its Second Fund and Announces Participation from Major Healthcare Systems (PR Newswire)
01:01AM	Loading…
Mar-23-26 01:01AM	ISRG- Not Cheap, But Delivering on Growth Expectations (MoneyShow)
Mar-13-26 02:38PM	Intuitive Surgical Stock Falls After Cybersecurity Breach Hits Internal Systems (GuruFocus.com)
11:47AM	Intuitive Surgical hit by phishing incident (MedTech Dive)
Mar-11-26 09:40AM	Oracle, Nike upgraded: Wall Street's top analyst calls (The Fly)
07:45AM	Here Are Wednesday's Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More (24/7 Wall St.)
05:20AM	Citi upgrades Intuitive Surgical to Buy on recent selloff (TipRanks)
05:10AM	Intuitive Surgical upgraded to Buy from Neutral at Citi (TipRanks)
Mar-10-26 01:39PM	Stryker Introduces SmartHospital Platform to Advance Connected Care (Zacks)
01:11PM	GEHC Wins FDA 510(k) Approval for View, Enhances Radiology Workflows (Zacks)
10:55AM	Here's Why You Should Retain CONMED Stock in Your Portfolio Now (Zacks)
09:34AM	Loading…
09:34AM	5 Medical Instruments Stocks to Buy Amid Huge Short-Term Price Upside (Zacks)
09:05AM	National Vision Gains 129.5% in a Year: What's Driving the Rally? (Zacks)
08:24AM	Should You Continue to Hold DGX Stock in Your Portfolio? (Zacks)
05:36AM	Intuitive Surgical, Inc. (ISRG) Announces the Completion of its Acquisition of the da Vinci and Ion Distribution Business (Insider Monkey)
02:48AM	SS Innovations raises $18.6M as surgical robot nears US market (MedTech Dive)
Mar-09-26 01:03PM	IDEXX Laboratories Stock Climbs 39.4% in a Year: What's Driving It? (Zacks)
11:53AM	Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment (Zacks)
09:30AM	Intuitive Surgical (ISRG) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
12:43AM	2 Healthcare Stocks with Exciting Potential and 1 We Avoid (StockStory)
Mar-06-26 05:50PM	Intuitive Surgical, Inc. (ISRG) Stock Moves -1.32%: What You Should Know (Zacks)
11:49AM	Here's Why You Should Add DaVita Stock to Your Portfolio for Now (Zacks)
11:44AM	BDX Secures CE Mark for Revello Stent to Treat Iliac Artery Disease (Zacks)
Mar-05-26 01:00PM	Veeva Systems' Stock Up After Q4 Earnings & Revenues Beat Estimates (Zacks)
12:46PM	BD Gains FDA Clearance for Surgiphor 1000mL Surgical Irrigation System (Zacks)
09:33AM	Here's Why You Should Retain INSP Stock in Your Portfolio for Now (Zacks)
09:31AM	Loading…
09:31AM	RGTI Stock Down Despite Q4 Earnings Top Estimates, Revenues Decline Y/Y (Zacks)
07:43AM	EYE Stock Up Following Q4 Earnings & Revenue Beat, Margins Rise (Zacks)
Mar-04-26 12:30PM	Here's Why You Should Retain Clover Stock in Your Portfolio for Now (Zacks)
10:50AM	Stryker Unveils Next-Gen Orthopedic Innovations at AAOS 2026 (Zacks)
09:00AM	This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar (Zacks)
07:52AM	Intuitive Surgical Expands Direct Operational Presence in Europe (Zacks)
Mar-03-26 08:15AM	Can Digital Subscriptions Become ISRG's New Revenue Stream in 2026? (Zacks)
06:42AM	BOTZ Is A Robotics ETF That Quietly Bets Big on AI Chips (24/7 Wall St.)
Mar-02-26 12:59PM	OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis (Zacks)
12:13PM	5 Stocks Racing Ahead as AI Supercharges Robotics (MarketBeat)
09:00AM	Here is What to Know Beyond Why Intuitive Surgical, Inc. (ISRG) is a Trending Stock (Zacks)
07:41AM	PEN Stock Up Following Q4 Earnings & Revenue Beat, Margins Rise (Zacks)
07:41AM	Integra Q4 Earnings & Revenues Beat Estimates, Margins Down, Stock Up (Zacks)
07:00AM	Intuitive Expands Investment and Footprint in Europe (GlobeNewswire)
06:27AM	Intuitive expands in Europe with purchase of distributor operations (MedTech Dive)
Mar-01-26 10:37PM	A Look Back at Surgical Equipment & Consumables - Specialty Stocks' Q4 Earnings: Intuitive Surgical (NASDAQ:ISRG) Vs The Rest Of The Pack (StockStory)
10:59AM	Is Becton, Dickinson and Company Stock Outperforming the Dow? (Barchart)
Feb-27-26 12:43PM	Clover Health Q4 Earnings Meet Estimates, Sales Beat, Membership Rises (Zacks)
12:38PM	CHE Stock Falls Post Q4 Earnings & Revenue Miss, Margins Crash (Zacks)
12:37PM	GEHC & UCSF Form 10-Year Alliance to Advance Imaging & Care Delivery (Zacks)
09:40AM	XRAY Stock Gains Despite Q4 Earnings Miss on Restructuring Initiative (Zacks)
07:42AM	TFX Q4 Earnings & Revenues Miss, Margins Down, Stock Up in After-Market (Zacks)
Feb-26-26 11:46AM	GEHC Unveils AI LOGIQ Ultrasound Systems to Boost Imaging & Workflow (Zacks)
11:22AM	Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises (Zacks)
11:21AM	A Decade From Now, You'll Regret Not Buying This 1 Small-Cap Stock (Barchart)
11:21AM	Intuitive Surgical or Abbott: Which MedTech Stock Is a Better Bet Now? (Zacks)
Feb-25-26 01:55PM	Merit Medical Q4 Earnings & Revenues Beat Estimate, Margins Expand (Zacks)
01:55PM	FMS Stock Rises as Q4 Earnings & Sales Beat Estimates, Margins Expand (Zacks)
11:57AM	Stryker Launches Synchfix EVT for Flexible Syndesmotic Fixation (Zacks)
11:50AM	TMDX Stock Rises as Q4 Earnings & Revenues Beat Estimates (Zacks)
09:09AM	Is Intuitive Surgical Stock Underperforming the Dow? (Barchart)
08:17AM	Top Robotics Stocks Worth Investing Now for Solid Returns (Zacks)
07:50AM	Alcon's Q4 Earnings Miss Estimates, Stock Falls, Revenues Rise Y/Y (Zacks)
07:26AM	TEM Q4 Earnings Miss, Revenues Beat, Stock Down in After-Market (Zacks)
Feb-24-26 12:40PM	BD Launches Urine Complete Cup Kit for Smarter Testing & Accuracy (Zacks)
10:11AM	The Zacks Analyst Blog Highlights Oracle, Intuitive Surgical, Analog Devices and Moving iMage Technologies (Zacks)
08:46AM	Zacks Industry Outlook Highlights Intuitive Surgical, Edwards Lifesciences and Electromed (Zacks)
08:46AM	HSIC Q4 Earnings & Revenues Beat Estimates, Margins Down (Zacks)
07:45AM	MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down (Zacks)
Feb-23-26 04:11PM	Top Research Reports for Oracle, Intuitive Surgical & Analog Devices (Zacks)
03:37PM	Da Vinci 5 Sparks Optimism Around Intuitive Surgical, Inc. (ISRG) (Insider Monkey)
12:42PM	ANGO Expands NanoKnife in Europe for Multi-Organ Tumor Ablation (Zacks)
08:53AM	3 Medical Instrument Stocks Banking on GenAI to Tackle Industry Woes (Zacks)
Feb-20-26 12:22PM	GE HealthCare Wins FDA Clearances for Next-Gen SIGNA MRI Portfolio (Zacks)
11:48AM	AMN Q4 Earnings Meet Estimates, Revenues Beat, Gross Margin Contracts (Zacks)
11:44AM	ITGR Shares Down Despite Q4 Earnings & Revenues Beat Estimates (Zacks)
09:11AM	TNDM Q4 Earnings & Revenues Beat Estimates, Gross Margin & Stock Up (Zacks)
Feb-19-26 12:08PM	STAA Gains FDA Nod to Expand EVO ICL Age Indication to 60 Years (Zacks)
11:01AM	ISRG's International Growth Outpaces US With 35% Procedure Volume (Zacks)
09:30AM	Is It Worth Investing in Intuitive Surgical (ISRG) Based on Wall Street's Bullish Views? (Zacks)
08:33AM	Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down (Zacks)
08:16AM	Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up (Zacks)
08:09AM	PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise (Zacks)
07:56AM	COR's MWI Animal Health to Merge With Covetrus in $3.5 Billion Deal (Zacks)
Feb-18-26 01:09PM	GEHC Expands BARDA Collaboration With $35M Boost for AI Ultrasound (Zacks)
10:53AM	Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook (Zacks)
09:51AM	SSKN Stock Falls Despite Meta-Analysis Backs Excimer Laser's Efficacy (Zacks)
09:48AM	Reasons to Hold HealthEquity Stock in Your Portfolio for Now (Zacks)
08:55AM	CRL Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise (Zacks)
Feb-17-26 01:11PM	Medtronic Posts Better-Than-Expected Earnings. Heres Why the Stock Is Falling. (Barrons.com)
11:20AM	Tempus AI & Median Partner to Add AI Lung Cancer Screening to Pixel (Zacks)
11:12AM	QDEL Expands Immunoassay Portfolio Via Lifotronic Supply Agreement (Zacks)
10:07AM	Labcorp Q4 Earnings Beat, Revenues Miss, Stock Down in Pre-Market (Zacks)
09:42AM	MDT Stock Up on Q3 Earnings and Revenue Beat, Margins Down (Zacks)
09:00AM	Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know (Zacks)
03:33AM	What Are Wall Street Analysts' Target Price for Intuitive Surgical Stock? (Barchart)
Feb-16-26 11:32AM	CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT (Zacks)
10:52AM	TMDX Wins Full FDA IDE Approval for Next-Gen OCS ENHANCE Heart Trial (Zacks)
10:05AM	Bruker's Q4 Earnings Lag Estimates, Margins Contract, Stock Down (Zacks)
Feb-13-26 12:35PM	DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth (Zacks)

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Curet Myriam	EVP & Chief Medical Officer	Mar 10 '26	Option Exercise	229.39	105	24,086	105	Mar 11 01:46 PM
Curet Myriam	EVP & Chief Medical Officer	Mar 10 '26	Sale	493.95	105	51,865	0	Mar 11 01:46 PM
MYRIAM CURET MCADAMS	Officer	Mar 10 '26	Proposed Sale	493.95	105	51,865		Mar 10 04:47 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Mar 06 '26	Sale	490.19	648	317,643	2,258	Mar 10 02:24 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Mar 09 '26	Sale	485.01	645	312,831	1,613	Mar 10 02:24 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Mar 04 '26	Sale	498.68	2,362	1,177,883	3,554	Mar 05 06:38 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Mar 05 '26	Sale	495.20	648	320,890	2,906	Mar 05 06:38 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Mar 03 '26	Sale	488.10	648	316,289	5,916	Mar 05 06:38 PM
MARK BROSIUS	Officer	Mar 05 '26	Proposed Sale	501.18	1,714	859,023		Mar 05 04:43 PM
BRIAN MILLER	Officer	Mar 04 '26	Proposed Sale	497.42	8,368	4,162,411		Mar 04 04:43 PM
Widman Fredrik	VP Corporate Controller	Feb 28 '26	Option Exercise	0.00	468	0	1,377	Mar 03 06:17 PM
Widman Fredrik	VP Corporate Controller	Feb 27 '26	Sale	499.71	249	124,428	909	Mar 03 06:17 PM
Widman Fredrik	VP Corporate Controller	Mar 03 '26	Sale	487.18	118	57,487	1,026	Mar 03 06:17 PM
Curet Myriam	EVP & Chief Medical Officer	Mar 02 '26	Option Exercise	208.90	125	26,112	5,262	Mar 03 05:34 PM
Curet Myriam	EVP & Chief Medical Officer	Mar 03 '26	Sale	487.18	4,728	2,303,387	409	Mar 03 05:34 PM
Curet Myriam	EVP & Chief Medical Officer	Mar 02 '26	Sale	492.59	125	61,574	5,137	Mar 03 05:34 PM
MARK BROSIUS	Officer	Mar 03 '26	Proposed Sale	496.25	3,327	1,651,024		Mar 03 04:32 PM
FREDRIK WIDMAN	Officer	Mar 03 '26	Proposed Sale	487.18	118	57,487		Mar 03 04:29 PM
MYRIAM CURET MCADAMS	Officer	Mar 03 '26	Proposed Sale	487.18	4,728	2,303,387		Mar 03 04:17 PM
Jeddi Iman	SVP & GM da Vinci Platforms &	Feb 28 '26	Option Exercise	0.00	9,004	0	10,618	Mar 03 12:53 PM
GUTHART GARY S	Director	Feb 28 '26	Option Exercise	0.00	28,840	0	36,848	Mar 03 12:25 PM
Samath Jamie	EVP & CFO & Enterprise Technol	Feb 28 '26	Option Exercise	0.00	11,525	0	20,709	Mar 02 07:41 PM
LOEB GARY	EVP & Chief Legal and Complian	Feb 28 '26	Option Exercise	0.00	3,148	0	8,082	Mar 02 06:40 PM
Charlton Henry L	EVP & Chief Commercial and Mkt	Feb 28 '26	Option Exercise	0.00	11,525	0	16,410	Mar 02 05:17 PM
Rosa David J.	Chief Executive Officer (CEO)	Feb 28 '26	Option Exercise	0.00	24,918	0	249,698	Mar 02 05:02 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Feb 28 '26	Option Exercise	0.00	9,255	0	10,719	Mar 02 04:48 PM
MYRIAM CURET MCADAMS	Officer	Mar 02 '26	Proposed Sale	492.59	125	61,574		Mar 02 04:09 PM
Curet Myriam	EVP & Chief Medical Officer	Feb 28 '26	Option Exercise	0.00	9,380	0	9,292	Mar 02 03:41 PM
Curet Myriam	EVP & Chief Medical Officer	Feb 27 '26	Sale	499.71	2,345	1,171,820	409	Mar 02 03:41 PM
WADORS PATRICIA L	SVP Chief Human Resources Offi	Feb 26 '26	Option Exercise	0.00	458	0	458	Feb 27 06:43 PM
WADORS PATRICIA L	SVP Chief Human Resources Offi	Feb 27 '26	Sale	499.71	220	109,936	0	Feb 27 06:43 PM
FREDRIK WIDMAN	Officer	Feb 27 '26	Proposed Sale	499.71	249	124,428		Feb 27 04:24 PM
MYRIAM CURET MCADAMS	Officer	Feb 27 '26	Proposed Sale	499.71	2,345	1,171,820		Feb 27 04:11 PM
PATRICIA WADORS	Officer	Feb 27 '26	Proposed Sale	499.71	220	109,936		Feb 27 04:09 PM
Jeddi Iman	SVP & GM da Vinci Platforms &	Feb 26 '26	Option Exercise	0.00	2,309	0	2,263	Feb 27 03:04 PM
Charlton Henry L	EVP & Chief Commercial and Mkt	Feb 26 '26	Option Exercise	0.00	2,747	0	5,679	Feb 27 02:53 PM
Samath Jamie	EVP & CFO & Enterprise Technol	Feb 26 '26	Option Exercise	0.00	3,396	0	10,295	Feb 27 02:45 PM
LOEB GARY	EVP & Chief Legal and Complian	Feb 26 '26	Option Exercise	0.00	2,442	0	5,389	Feb 27 02:36 PM
Curet Myriam	EVP & Chief Medical Officer	Feb 26 '26	Option Exercise	0.00	4,654	0	3,549	Feb 27 02:00 PM
Widman Fredrik	VP Corporate Controller	Feb 26 '26	Option Exercise	0.00	989	0	1,346	Feb 27 01:52 PM
Rosa David J.	Chief Executive Officer (CEO)	Feb 26 '26	Option Exercise	0.00	6,105	0	233,783	Feb 27 01:42 PM
GUTHART GARY S	Director	Feb 26 '26	Option Exercise	0.00	8,393	0	10,954	Feb 27 01:32 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Feb 26 '26	Option Exercise	0.00	2,595	0	2,382	Feb 27 01:19 PM
BRIAN MILLER	Officer	Feb 18 '26	Proposed Sale	493.35	647	319,197		Feb 18 04:37 PM
Curet Myriam	EVP & Chief Medical Officer	Feb 10 '26	Option Exercise	25.54	943	24,086	1,247	Feb 11 05:37 PM
Curet Myriam	EVP & Chief Medical Officer	Feb 11 '26	Sale	494.96	421	208,378	409	Feb 11 05:37 PM
Curet Myriam	EVP & Chief Medical Officer	Feb 10 '26	Sale	494.65	105	51,938	830	Feb 11 05:37 PM
Widman Fredrik	VP Corporate Controller	Feb 10 '26	Option Exercise	0.00	567	0	1,095	Feb 11 05:17 PM
Widman Fredrik	VP Corporate Controller	Feb 11 '26	Sale	494.96	133	65,830	660	Feb 11 05:17 PM
FREDRIK WIDMAN	Officer	Feb 11 '26	Proposed Sale	494.96	133	65,830		Feb 11 04:05 PM
MYRIAM CURET MCADAMS	Officer	Feb 11 '26	Proposed Sale	494.96	421	208,378		Feb 11 04:02 PM
Rosa David J.	Chief Executive Officer (CEO)	Feb 10 '26	Option Exercise	0.00	1,436	0	230,294	Feb 10 04:28 PM
GUTHART GARY S	Director	Feb 10 '26	Option Exercise	0.00	2,633	0	6,327	Feb 10 04:18 PM
MYRIAM CURET MCADAMS	Officer	Feb 10 '26	Proposed Sale	494.65	105	51,938		Feb 10 04:04 PM
LOEB GARY	EVP & Chief Legal and Complian	Feb 10 '26	Option Exercise	0.00	315	0	3,876	Feb 10 03:51 PM
Jeddi Iman	SVP & GM da Vinci Platforms &	Feb 10 '26	Option Exercise	0.00	838	0	894	Feb 10 03:26 PM
Samath Jamie	EVP & CFO & Enterprise Technol	Feb 10 '26	Option Exercise	0.00	1,077	0	8,295	Feb 10 03:16 PM
Charlton Henry L	EVP & Chief Commercial and Mkt	Feb 10 '26	Option Exercise	0.00	1,077	0	4,189	Feb 10 02:16 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Feb 10 '26	Option Exercise	0.00	838	0	1,025	Feb 10 01:54 PM
Curet Myriam	EVP & Chief Medical Officer	Jan 29 '26	Option Exercise	208.90	126	26,321	126	Jan 30 09:16 PM
Curet Myriam	EVP & Chief Medical Officer	Jan 29 '26	Sale	520.02	126	65,523	0	Jan 30 09:16 PM
MYRIAM CURET MCADAMS	Officer	Jan 29 '26	Proposed Sale	520.02	126	65,523		Jan 29 04:01 PM
Curet Myriam	EVP & Chief Medical Officer	Jan 27 '26	Option Exercise	218.25	230	50,198	125	Jan 28 04:34 PM
Curet Myriam	EVP & Chief Medical Officer	Jan 27 '26	Sale	532.61	230	122,500	0	Jan 28 04:34 PM
GUTHART GARY S	Director	Jan 27 '26	Option Exercise	174.26	25,500	4,443,546	28,194	Jan 28 04:20 PM
GUTHART GARY S	Director	Jan 27 '26	Sale	530.10	24,500	12,987,403	3,694	Jan 28 04:20 PM
GUTHART GARY S	Director	Jan 27 '26	Sale	531.52	2,800	1,488,269	15,720	Jan 28 04:20 PM
GARY S GUTHART	Officer	Jan 27 '26	Proposed Sale	530.10	24,500	12,987,403		Jan 27 05:18 PM
MYRIAM CURET MCADAMS	Officer	Jan 27 '26	Proposed Sale	532.61	230	122,500		Jan 27 04:01 PM
GUTHART GARY S	Officer	Jan 27 '26	Proposed Sale	531.52	2,800	1,488,269		Jan 27 11:11 AM
Brosius Mark	See Remarks	Dec 15 '25	Sale	548.49	464	254,499	131	Dec 17 06:59 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Dec 12 '25	Option Exercise	79.64	4,500	358,370	5,407	Dec 15 06:52 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Dec 12 '25	Sale	547.36	4,500	2,463,120	907	Dec 15 06:52 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Dec 15 '25	Sale	548.49	464	254,499	443	Dec 15 06:52 PM
MARK BROSIUS	Officer	Dec 12 '25	Proposed Sale	547.36	5,276	2,887,871		Dec 12 04:19 PM
Curet Myriam	EVP & Chief Medical Officer	Dec 10 '25	Option Exercise	229.39	104	23,857	104	Dec 10 06:23 PM
Curet Myriam	EVP & Chief Medical Officer	Dec 10 '25	Sale	559.90	104	58,230	0	Dec 10 06:23 PM
MYRIAM CURET MCADAMS	Officer	Dec 10 '25	Proposed Sale	559.90	104	58,230		Dec 10 04:01 PM
Curet Myriam	EVP & Chief Medical Officer	Dec 01 '25	Option Exercise	208.90	125	26,112	125	Dec 02 04:16 PM
Curet Myriam	EVP & Chief Medical Officer	Dec 01 '25	Sale	568.99	125	71,124	0	Dec 02 04:16 PM
GUTHART GARY S	Executive Chair of the Board o	Dec 01 '25	Option Exercise	139.52	25,500	3,557,760	25,500	Dec 02 12:50 PM
GUTHART GARY S	Executive Chair of the Board o	Dec 01 '25	Sale	570.89	22,806	13,019,722	2,694	Dec 02 12:50 PM
GARY S GUTHART	Officer	Dec 01 '25	Proposed Sale	570.89	22,806	13,019,722		Dec 01 04:48 PM
MYRIAM CURET MCADAMS	Officer	Dec 01 '25	Proposed Sale	568.99	125	71,124		Dec 01 04:05 PM
Charlton Henry L	EVP & Chief Commercial and Mkt	Nov 12 '25	Option Exercise	229.95	9,000	2,069,552	10,688	Nov 13 01:55 PM
Charlton Henry L	EVP & Chief Commercial and Mkt	Nov 12 '25	Sale	580.00	13,731	7,963,980	3,056	Nov 13 01:55 PM
BARRATT CRAIG H	Director	Nov 12 '25	Option Exercise	71.32	750	53,492	750	Nov 13 01:46 PM
BARRATT CRAIG H	Director	Nov 12 '25	Sale	580.00	750	435,000	0	Nov 13 01:46 PM
HENRY CHARLTON	Officer	Nov 12 '25	Proposed Sale	580.00	13,731	7,963,980		Nov 12 04:04 PM
CRAIG H BARRATT	Director	Nov 12 '25	Proposed Sale	580.00	750	435,000		Nov 12 04:01 PM
Curet Myriam	EVP & Chief Medical Officer	Nov 10 '25	Option Exercise	229.39	105	24,086	105	Nov 12 02:12 PM
Curet Myriam	EVP & Chief Medical Officer	Nov 10 '25	Sale	560.00	105	58,800	0	Nov 12 02:12 PM
Miller Brian Edward	EVP & Chief Digital Officer	Nov 10 '25	Option Exercise	216.50	3,500	757,746	7,960	Nov 12 02:03 PM
Miller Brian Edward	EVP & Chief Digital Officer	Nov 10 '25	Sale	575.00	3,500	2,012,500	5,758	Nov 12 02:03 PM
BRIAN MILLER	Officer	Nov 10 '25	Proposed Sale	575.00	3,500	2,012,500		Nov 10 06:18 PM
MYRIAM CURET MCADAMS	Officer	Nov 10 '25	Proposed Sale	560.00	105	58,800		Nov 10 04:01 PM
Widman Fredrik	VP Corporate Controller	Nov 05 '25	Option Exercise	75.65	2,067	156,368	2,381	Nov 06 02:17 PM
Widman Fredrik	VP Corporate Controller	Nov 05 '25	Sale	550.00	2,067	1,136,850	473	Nov 06 02:17 PM
FREDRIK WIDMAN	Officer	Nov 05 '25	Proposed Sale	550.00	2,067	1,136,850		Nov 05 04:36 PM
Curet Myriam	EVP & Chief Medical Officer	Oct 28 '25	Option Exercise	234.27	7,562	1,771,513	5,383	Oct 29 07:48 PM

Open in Screener

NKTR

Nektar Therapeutics

Apr 21 • 09:49AM ET

103.67

+3.32 3.31 %

Healthcare • Biotechnology • USA • NASD

NKTR Nektar Therapeutics daily Stock Chart

Peers: AMGN BIIB VRTX GILD REGN INCY IONS SRPT EXEL NBIX

| Held by: VTI VXF SCHA XPH IHE PRFZ VHT LFSC DWAS ITOT

Index	-	P/E	-	EPS (ttm)	-10.22	Insider Own	3.95%	Shs Outstand	28.69M	Perf Week	27.58%
Market Cap	2.97B	Forward P/E	-	EPS next Y	-12.00	Insider Trans	-0.74%	Shs Float	27.56M	Perf Month	43.55%
Enterprise Value	2.88B	PEG	-	EPS next Q	-1.65	Inst Own	73.56%	Short Float	13.29%	Perf Quarter	186.14%
Income	-164.08M	P/S	53.85	EPS this Y	2.32%	Inst Trans	24.22%	Short Ratio	3.16	Perf Half Y	79.45%
Sales	55.23M	P/B	23.52	EPS next Y	-26.31%	ROA	-56.17%	Short Interest	3.66M	Perf YTD	145.20%
Book/sh	4.41	P/C	12.10	EPS next 5Y	-8.72%	ROE	-217.94%	52W High	109.00 -4.89%	Perf Year	1004.22%
Cash/sh	8.57	P/FCF	-	EPS past 3/5Y	30.93% 23.59%	ROIC	-75.18%	52W Low	7.99 1197.50%	Perf 3Y	694.41%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-15.66% -18.43%	Gross Margin	98.14%	Volatility	5.97% 6.41%	Perf 5Y	-64.97%
Dividend TTM	-	EV/Sales	52.10	EPS Y/Y TTM	-17.07%	Oper. Margin	-236.77%	ATR (14)	5.66	Perf 10Y	-56.17%
Dividend Ex-Date	-	Quick Ratio	4.97	Sales Y/Y TTM	-43.89%	Profit Margin	-297.07%	RSI (14)	82.31	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	4.97	EPS Q/Q	-448.62%	SMA20	31.75%	Beta	-0.59	Target Price	140.62
Payout	-	Debt/Eq	1.66	Sales Q/Q	-25.25%	SMA50	41.31%	Rel Volume	2.40	Prev Close	100.35
Employees	63	LT Debt/Eq	1.43	Earnings	Mar 12 AMC	SMA200	102.28%	Avg Volume	1.16M	Price	103.67
IPO	May 03, 1994	Option/Short	Yes / Yes	EPS/Sales Surpr.	28.05% 114.01%	Trades		Volume	268,454	Change	3.31%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-24-26	Initiated	Wedbush	Neutral	$70
Mar-17-26	Initiated	TD Cowen	Buy
Feb-10-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-26-25	Initiated	Citigroup	Buy	$102
Jun-24-25	Reiterated	H.C. Wainwright	Buy	$6.50 → $120
Jun-24-25	Reiterated	BTIG Research	Buy	$60 → $100
Apr-11-25	Upgrade	Jefferies	Hold → Buy	$2
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform	$6
Jan-08-25	Initiated	B. Riley Securities	Buy	$4
Dec-10-24	Initiated	H.C. Wainwright	Buy	$6.50
Nov-04-24	Initiated	Piper Sandler	Overweight	$7
Sep-30-24	Resumed	BTIG Research	Buy	$4
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$2
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3

Show Previous Ratings

Apr-20-26 04:01PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire) +18.25%
02:34PM	Market Feels Weak, But Stocks Tell Stories (GuruFocus.com)
12:43PM	Nektar Therapeutics Adds To Its 129% Two-Month Run With Alopecia News (Investor's Business Daily)
11:43AM	This Biotech Stock Soars on Hair Loss Trial Results. It's Not a Cure for Baldness. (Barrons.com)
08:01AM	Nektar surges again as alopecia drug shows new promise in extension study (BioPharma Dive)
07:30AM	Loading…
07:30AM	52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin (PR Newswire)
Apr-19-26 12:00PM	Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026 (PR Newswire)
Mar-28-26 12:36PM	Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting (PR Newswire)
Mar-27-26 10:34AM	Short Squeeze Stocks: The Usual Suspects, & One Newcomer (Schaeffer's Research)
Mar-23-26 08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
Mar-20-26 10:00AM	Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting (PR Newswire)
Mar-17-26 09:33AM	DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls (The Fly)
Mar-16-26 03:09AM	Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR (PR Newswire)
Mar-13-26 08:30AM	Nektar Therapeutics Q4 2025 Earnings Call Summary (Moby)
Mar-12-26 11:05PM	Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Highlights: Promising Phase 2B Results and ... (GuruFocus.com)
04:41PM	Loading…
04:41PM	Nektar: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
Mar-10-26 08:30AM	Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights NKTR (Business Wire)
07:10AM	Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates (Zacks)
Mar-06-26 06:00PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-05-26 10:00AM	Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-26-26 06:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets (PR Newswire) -6.35%
Feb-25-26 09:55AM	Wall Street Analysts Think Nektar (NKTR) Could Surge 89.8%: Read This Before Placing a Bet (Zacks)
Feb-24-26 06:00PM	Nektar Therapeutics to Participate in Two Investor Conferences in March (PR Newswire) -7.06%
Feb-23-26 12:07PM	GeneDx Q4 Earnings Call Highlights (MarketBeat)
Feb-17-26 07:00AM	Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis (PR Newswire)
Feb-13-26 04:15PM	Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-11-26 10:23PM	Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering (PR Newswire) +18.48% +7.01%
08:08AM	Nektar (NKTR) Soars 51.1%: Is Further Upside Left in the Stock? (Zacks)
07:42AM	Nektars stock rises 51% on Phase II Rezpeg AD maintenance win (Clinical Trials Arena)
07:35AM	Loading…
07:35AM	Why Is Nektar Therapeutics Stock Gaining Wednesday? (Benzinga)
02:07AM	Nektar Therapeutics Touts 52-Week ResPEG Data in Atopic Dermatitis, Eyes Phase 3 Launch in Q2 (MarketBeat)
Feb-10-26 04:07PM	Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. (Investor's Business Daily) +51.07%
04:05PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire)
11:57AM	Nektar Therapeutics Stock Is Trending Tuesday: What's Going On? (Benzinga)
07:13AM	Nektar, continuing comeback, says eczema drugs effects hold up in follow-up study (BioPharma Dive)
07:00AM	New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing (PR Newswire)
Feb-09-26 04:15PM	Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026 (PR Newswire)
Feb-02-26 10:02PM	Nektar Therapeutics (NKTR): A Bull Case Theory (Insider Monkey)
Jan-30-26 04:10PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.96%
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
Jan-07-26 08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-05-26 05:05PM	Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead (Motley Fool)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-21-25 07:31AM	Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) (Insider Monkey)
Dec-16-25 07:30AM	REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata (PR Newswire) -7.77%
06:24AM	Nektar sees silver lining as autoimmune drug narrowly misses in alopecia study (BioPharma Dive)
Dec-15-25 06:00PM	Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 (PR Newswire)
Dec-08-25 12:00PM	Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy (Zacks)
Dec-05-25 06:00PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-01-25 09:55AM	Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade (Zacks) -6.29%
Nov-26-25 09:43AM	Autodesk upgraded, Nio downgraded: Wall Street's top analyst calls (The Fly) +8.85%
Nov-23-25 07:02AM	Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now? (Insider Monkey)
Nov-20-25 06:57AM	Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. (Motley Fool) -8.68%
Nov-13-25 09:55AM	Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect? (Zacks) -6.45%
Nov-08-25 05:45PM	New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
Nov-07-25 10:11AM	Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
12:07AM	Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Nov-06-25 05:55PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:06PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-03-25 10:00AM	Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) -7.72%
Oct-30-25 06:00PM	Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London (PR Newswire) +5.32%
10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 06:00PM	Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
09:55AM	Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High? (Zacks)
Oct-26-25 06:06AM	Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation (Insider Monkey)
Oct-22-25 08:00AM	Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
Oct-13-25 08:37AM	This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street (Motley Fool) +5.63%
Oct-05-25 08:41AM	Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September (Motley Fool)
Sep-25-25 05:22AM	Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock? (Zacks) -7.81%
Sep-21-25 06:43PM	These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? (Motley Fool)
Sep-18-25 05:34PM	Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today (Motley Fool) +15.06% -6.16%
12:23PM	EADV 25: Nektar presents data from AD candidate that sent stocks flying (Clinical Trials Arena)
08:45AM	Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 (PR Newswire)
Sep-09-25 07:00AM	Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 (PR Newswire) +9.56%
Sep-08-25 11:27AM	NKTR Shares Surge 38.2% in a Week: Here's What You Should Know (Zacks) +10.33%
Sep-05-25 01:32PM	Why Nektar Therapeutics Rippled Higher This Week (Motley Fool) +11.67%
Sep-03-25 07:00PM	Nektar Therapeutics to Participate in Two Investor Conferences in September (PR Newswire) +26.02%
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-08-25 06:15PM	Why Nektar Therapeutics Stock Popped 6% on Friday (Motley Fool) +6.02%
11:45AM	Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y (Zacks)
Aug-07-25 05:30PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:33PM	Nektar: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-05-25 06:10PM	Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-04-25 11:55AM	Nektar Gears Up to Report Q2 Earnings: What's in the Cards? (Zacks)
10:00AM	Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-31-25 06:00PM	Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets (PR Newswire) +5.90%
Jul-29-25 09:00AM	Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata (PR Newswire)
01:31AM	Nektar Therapeutics (NKTR) Announced Positive results for Rezpegaldesleukin (Insider Monkey)
Jul-21-25 11:02AM	3 Bullish Biotech Stocks With Explosive Growth Trends (MarketBeat)
Jul-06-25 04:01AM	Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin (Insider Monkey)
Jul-03-25 07:00PM	Why Nektar Therapeutics Stock Dived by 3% Today (Motley Fool) -5.21%
Jul-02-25 04:15PM	Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jul-01-25 07:17AM	Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire)
Jun-30-25 04:02PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire)
02:21PM	Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains (MarketBeat)
Jun-28-25 08:15AM	Nektar Jumps 157% on Drug Trial Data-Can It Go Even Higher? (MarketBeat)

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wilson Mark Andrew	Former Officer	Mar 13 '26	Proposed Sale	72.64	78,510	5,702,966		Mar 13 01:04 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 18 '26	Sale	73.00	180	13,140	21,174	Feb 20 07:10 PM
ROBIN HOWARD W	President & CEO	Feb 18 '26	Sale	73.00	423	30,879	75,489	Feb 20 07:10 PM
ROBIN HOWARD W	Officer	Feb 18 '26	Proposed Sale	73.00	423	30,878		Feb 18 03:47 PM
Zalevsky Jonathan	Officer	Feb 18 '26	Proposed Sale	73.00	180	13,140		Feb 18 03:15 PM
Zalevsky Jonathan	Chief R&D Officer	Jan 20 '26	Sale	35.67	3,867	137,936	21,354	Jan 22 07:31 PM
Zalevsky Jonathan	Officer	Jan 20 '26	Proposed Sale	35.67	3,867	137,946		Jan 20 04:21 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 25 '25	Sale	54.28	1,157	62,802	18,971	Nov 25 08:30 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 25 '25	Sale	54.28	630	34,196	21,585	Nov 25 08:29 PM
ROBIN HOWARD W	President & CEO	Nov 25 '25	Sale	54.28	2,207	119,796	54,245	Nov 25 08:28 PM
ROBIN HOWARD W	Officer	Nov 25 '25	Proposed Sale	58.82	2,207	129,812		Nov 25 03:35 PM
Wilson Mark Andrew	Officer	Nov 25 '25	Proposed Sale	58.82	630	37,056		Nov 25 03:32 PM
Zalevsky Jonathan	Officer	Nov 25 '25	Proposed Sale	58.82	1,157	68,053		Nov 25 03:28 PM
ROBIN HOWARD W	President & CEO	Sep 09 '25	Sale	46.69	6,666	311,214	49,342	Sep 11 09:01 PM
ROBIN HOWARD W	Officer	Sep 09 '25	Proposed Sale	46.69	6,666	311,205		Sep 09 04:57 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 04 '25	Sale	33.52	1,721	57,693	17,462	Sep 08 08:32 PM
ROBIN HOWARD W	President & CEO	Sep 05 '25	Sale	38.53	6,666	256,851	56,008	Sep 08 08:31 PM
ROBIN HOWARD W	President & CEO	Sep 04 '25	Sale	33.70	5,166	174,108	62,674	Sep 08 08:31 PM
ROBIN HOWARD W	Officer	Sep 05 '25	Proposed Sale	38.53	6,666	256,838		Sep 05 04:37 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 02 '25	Sale	30.10	485	14,598	19,183	Sep 04 09:02 PM
ROBIN HOWARD W	President & CEO	Sep 02 '25	Sale	30.16	1,500	45,240	67,840	Sep 04 09:01 PM
ROBIN HOWARD W	Officer	Sep 04 '25	Proposed Sale	33.70	5,166	174,119		Sep 04 05:06 PM
Zalevsky Jonathan	Officer	Sep 04 '25	Proposed Sale	33.52	1,721	57,688		Sep 04 04:19 PM
Zalevsky Jonathan	Officer	Sep 02 '25	Proposed Sale	30.10	485	14,600		Sep 02 04:45 PM
ROBIN HOWARD W	Officer	Sep 02 '25	Proposed Sale	30.16	1,500	45,244		Sep 02 04:42 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 19 '25	Sale	26.59	725	19,278	19,668	Aug 21 09:05 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 19 '25	Sale	26.59	676	17,975	20,312	Aug 21 09:04 PM
ROBIN HOWARD W	President & CEO	Aug 19 '25	Sale	26.59	1,573	41,826	69,340	Aug 21 09:03 PM
ROBIN HOWARD W	Officer	Aug 19 '25	Proposed Sale	26.59	1,573	41,826		Aug 19 03:24 PM
Wilson Mark Andrew	Officer	Aug 19 '25	Proposed Sale	26.59	676	17,975		Aug 19 03:24 PM
Zalevsky Jonathan	Officer	Aug 19 '25	Proposed Sale	26.59	725	19,278		Aug 19 03:20 PM
Zalevsky Jonathan	Chief R&D Officer	May 19 '25	Sale	0.67	10,712	7,177	305,892	May 21 08:08 PM
Wilson Mark Andrew	Chief Legal Officer	May 19 '25	Sale	0.67	9,996	6,697	314,296	May 21 08:07 PM
ROBIN HOWARD W	President & CEO	May 19 '25	Sale	0.67	23,208	15,549	1,063,693	May 21 08:07 PM
Zalevsky Jonathan	Officer	May 19 '25	Proposed Sale	0.67	10,712	7,191		May 19 03:49 PM
Wilson Mark Andrew	Officer	May 19 '25	Proposed Sale	0.67	9,996	6,710		May 19 03:44 PM
ROBIN HOWARD W	Officer	May 19 '25	Proposed Sale	0.67	23,208	15,580		May 19 03:40 PM

ISRG

Intuitive Surgical Inc

NKTR

Nektar Therapeutics

Upgrade your Finviz experience